Dr. Augustine Lee, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Maryland School of Medicine (1997)
- Years since graduation
- 29
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 1,502
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1997Medical school: University of Maryland School of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
FL license ME76906
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Mayo Clinic Jacksonville, FL
- Flagler Hospital Saint Augustine, FL
Medical groups
- Mayo Clinic Jacksonville (1,615 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,502
- Services billed
- 3,875
- Patients’ average age
- 73
| Service | Times | Patients |
|---|---|---|
| Test to examine how well the lungs exchange gases | 280 | 274 |
| Test to determine lung volumes using sensors | 242 | 238 |
| Test to measure expiratory airflow and volume | 232 | 213 |
| Test to measure expiratory airflow and volume changes before and after medication administration | 128 | 127 |
| Established patient office or other outpatient visit, 40-54 minutes | 119 | 99 |
| Established patient office or other outpatient visit, 30-39 minutes | 107 | 102 |
| Methacholine chloride administered as inhalation solution through a nebulizer, per 1 mg | 92 | 28 |
| New patient office or other outpatient visit, 60-74 minutes | 76 | 76 |
| Test for exercise-induced lung stress | 61 | 59 |
| Inhalation treatment for airway obstruction or sputum production | 56 | 52 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ofev (nintedanib esylate) | 78 |
| Mycophenolate Mofetil Other prescribers in Jacksonville, FL | 65 |
| Prednisone Other prescribers in Jacksonville, FL | 55 |
| Spiriva Respimat (tiotropium bromide) Other prescribers in Jacksonville, FL | 36 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Jacksonville, FL | 35 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Jacksonville, FL | 33 |
| Roflumilast Other prescribers in Jacksonville, FL | 31 |
| Pirfenidone | 23 |
| Montelukast Sodium Other prescribers in Jacksonville, FL | 20 |
| Methotrexate (methotrexate sodium) Other prescribers in Jacksonville, FL | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $4,042 in total to this clinician.
| Boehringer Ingelheim Pharmaceuticals, Inc. | $3,572 |
|---|---|
| Jazz Pharmaceuticals Inc. | $145 |
| Insmed, Inc. | $130 |
| Verona Pharma, Inc. | $125 |
| AstraZeneca Pharmaceuticals LP | $70.64 |
| Consulting Fee | $3,400 |
|---|---|
| Food and Beverage | $642 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Oct 8, 2025 | Consulting Fee | $3,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 2 companies. The companies reported $210,690 in research payments for these studies, mostly to the institutions running them.
- Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
United Therapeutics Corporation · Recruiting · NCT05943535 - Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease
United Therapeutics Corporation · Enrolling by invitation · NCT04905693 - Study of Efficacy and Safety of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis
United Therapeutics Corporation · Completed · NCT04708782 - Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Cumberland Pharmaceuticals, Inc. · Recruiting · NCT05571059
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.